SBP GROUP (01177.HK): TQ-A3334, Bepirovirsen Data Picked for AASLD
- On 14 October 2026, SBP GROUP (01177.HK) said TQ-A3334 data was selected as an AASLD 2026 late-breaking abstract, with Bepirovirsen picked for 10 presentations.
- The TQ-A3334 LBA is a randomised, double-blind, placebo-controlled phase II trial assessing 48-week efficacy and safety in NAs-treated chronic HBV patients.
NewTimeSpace News: On 14 October 2026, Sino Biopharmaceutical Limited (01177.HK) announced that a clinical study of TQ-A3334, a Class 1 innovative drug developed in-house by its unit Chia Tai Tianqing, was selected as a late-breaking abstract (LBA) for the 2026 AASLD annual meeting and will be presented orally. Bepirovirsen, the ASO product under its strategic collaboration with GSK, was selected for two oral and eight poster presentations, including one distinguished poster.
The TQ-A3334 LBA covers the efficacy and safety of an oral TLR7 agonist through 48 weeks in NAs-treated chronic HBV infection in a randomised, double-blind phase II trial. TQ-A3334 is an oral selective TLR7 agonist that reshapes anti-HBV immune responses. Bepirovirsen is a triple-mechanism investigational antisense oligonucleotide approved in Japan in August 2026, with US FDA fast track, priority review and breakthrough therapy designations.
- SBP GROUP (01177.HK): TQC3721 Phase III completes enrolment
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- SBP GROUP (01177.HK): NDA for TQH2722 "IL-4Rα Antibody" Accepted for Review
- SBP GROUP (01177.HK): NDA for TQB2102 "HER2 Bispecific ADC" Accepted for Review
- SBP GROUP (01177.HK): Preclinical Data of Oral STAT6 Degrader TQH5528 Presented at ERS 2026
